Guide for Mectizan® Donation to Accelerate Lymphatic Filariasis Elimination in countries where onchocerciasis is not co-endemic

This downloadable guide provides information on the new WHO strategy to use ivermectin (Mectizan®), albendazole, and diethylcarbamazine (DEC) for LF elimination in countries where river blindness in not endemic. 

In November 2017, the World Health Organization (WHO) published a new guideline on alternative mass drug administration (MDA) regimens to eliminate lymphatic filariasis (LF).

Adding to existing strategies, the new guideline recommends the addition of ivermectin to diethylcarbamazine (DEC) and albendazole (alb) to accelerate the elimination of LF where river blindness (onchocerciasis) is not co-endemic based on the following criteria:

a) implementation units (IUs) that have not started or have fewer than 4 effective rounds of DEC and Alb;

b) IUs that have not met the appropriate epidemiological targets in sentinel and spot check site surveys or in transmission assessment survey (TAS) despite meeting drug coverage targets;

c) communities where post-MDA or post-validation surveillance identifies infection suggesting local transmission. 

Supporting documents:

Annex 2: Agreement for the application of Mectizan® donation for the Elimination of Lymphatic Filariasis

PCT AE Reporting Form